The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells

CD95 in cancer: tool or target?

(2013) Ana Martin-Villalba et al.   TRENDS IN MOLECULAR MEDICINE

Modulation of CD4+ T-cell activation by CD95 co-stimulation

(2010) M Paulsen et al.   CELL DEATH AND DIFFERENTIATION

CD95 promotes tumour growth

(2010) Lina Chen et al.   NATURE

WT1 mutations in T-ALL

(2009) V. Tosello et al.   BLOOD

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

(2009) J Y Zhu et al.   CELL DEATH AND DIFFERENTIATION

Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

(2009) A Renneville et al.   LEUKEMIA

Concepts of activated T cell death

(2008) Dirk Brenner et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party

(2008) Priya Virappane et al.   JOURNAL OF CLINICAL ONCOLOGY

WT1 protein expression in childhood acute leukemia

(2007) Gunter Kerst et al.   AMERICAN JOURNAL OF HEMATOLOGY